|
|
|
|
Department of Medicinal Chemistry, Solvay Pharmaceuticals Research
Laboratories, 1380 DA Weesp, The Netherlands (W.K., P.J.S., A.R.S.,
I.v.W.),
Division of Medicinal Chemistry, Leiden/Amsterdam Center for
Drug Research, 2300 RA Leiden, The Netherlands (R. Link., A.P.I.J.);
and
Division of Medicinal Chemistry, Leiden/Amsterdam Center for Drug
Research, 1081 HV Amsterdam, The Netherlands (R. Leurs.).
We studied the stereoselective interaction between
aryloxypropanolamines and the human 5-hydroxytryptamine1A
(5-HT1A) receptor. R- and
S-enantiomers of propranolol, penbutolol, and alprenolol were investigated for their ability to bind to human 5-HT1A
wild-type and Asn386Val mutant receptors. Asn386 seemed to act as a
chiral discriminator. Although both aryloxypropanol enantiomers
displayed lower affinity for the mutant receptors, the affinities for
the S-enantiomers were more affected. Receptor affinities of
other structurally unrelated 5-HT1A ligands were not
decreased by the mutation of Asn386 to valine. In addition, a series of
analogues of propranolol with structural variation in the
oxypropanolamine moiety was synthesized, and affinities for wild-type
and Asn386Val mutant 5-HT1A receptors were determined. Both
the hydroxyl and the ether oxygen atoms of the oxypropanol moiety seem
to be required for binding at wild-type 5-HT1A receptors.
The hydroxyl group of propranolol probably directly interacts with
Asn386. The ether oxygen atom may be important for steric reasons but
can also be involved in a direct interaction with Asn386. These
findings are in agreement with the interactions of
aryloxypropanolamines with Asn386 in rat 5-HT1A receptors
that we previously proposed. The loss of affinity for propranolol by
the Asn386Val mutation could be regained by replacement of the hydroxyl
group of the ligand by a methoxy group. This modification of the
propranolol structure has no effect on the affinity of both enantiomers
for the wild-type 5-HT1A receptor, which provides an
alternative hypothesis for the interaction of Asn386 with the
oxypropanol oxygen atoms. According to this novel hypothesis, the
oxypropanol oxygen atoms may both act as hydrogen bond acceptors from
the NH2 group of Asn386.
This article has been cited by other articles:
![]() |
J. G. Baker, R. G. W. Proudman, N. C. Hawley, P. M. Fischer, and S. J. Hill Role of Key Transmembrane Residues in Agonist and Antagonist Actions at the Two Conformations of the Human {beta}1-Adrenoceptor Mol. Pharmacol., November 1, 2008; 74(5): 1246 - 1260. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Zuurmond, J. Hessling, K. Blüml, M. Lohse, and A. P. Ijzerman Study of Interaction between Agonists and Asn293 in Helix VI of Human beta 2-Adrenergic Receptor Mol. Pharmacol., November 1, 1999; 56(5): 909 - 916. [Abstract] [Full Text] |
||||
![]() |
K. Wieland, A. M. T. Laak, M. J. Smit, R. Kuhne, H. Timmerman, and R. Leurs Mutational Analysis of the Antagonist-binding Site of the Histamine H1 Receptor J. Biol. Chem., October 15, 1999; 274(42): 29994 - 30000. [Abstract] [Full Text] [PDF] |
||||